Genetics of Plasma soluble Receptor for Advanced Glycation End-products and cardiovascular outcomes in a community-based population: Results from the Atherosclerosis Risk in Communities Study

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Maruthur, Nisa M ^a,b,c   Li, Man ^c   Halushka, Marc K ^a   Astor, Brad C ^d   Pankow, James S ^e   Boerwinkle, Eric ^f   Coresh, Josef ^a,b,c   Selvin, Elizabeth ^a,b,c   Linda Kao, Wen Hong ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; NOTCH4 RECEPTOR;

ADULT; ALLELE; ARTICLE; ATHEROSCLEROSIS; BLACK PERSON; BODY MASS; CAUCASIAN; CHROMOSOME 6; COMMUNITY ASSESSMENT; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; OUTCOME ASSESSMENT; POPULATION GENETICS; POPULATION RESEARCH; PREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SRAGE GENE; AFRICAN AMERICAN; BLOOD; CARDIOVASCULAR DISEASES; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METAGENOMICS; MORTALITY; RISK FACTOR; SURVIVAL ANALYSIS;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AFRICAN AMERICANS; ALLELES; CARDIOVASCULAR DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; METAGENOMICS; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84939145657     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128452     Document Type: Article

References (44)

1. Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes. 2011; 60(9):2379-85. doi: 10.2337/db11-0291 PMID: 21771973; PubMed Central PMCID: PMC3161327.
2. Semba RD, Ferrucci L, Sun K, Beck J, Dalal M, Varadhan R, et al. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older communitydwelling women. Aging Clin Exp Res. 2009; 21(2):182-90. PMID: 19448391; PubMed Central PMCID: PMC2684987.
3. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis. 2009; 204(1):288-92. doi: 10.1016/j.atherosclerosis.2008.08.026 PMID: 18926539.
4. Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, Coresh J, et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 2013; 62(6):2116-21. doi: 10.2337/db12-1528 PMID: 23396398; PubMed Central PMCID: PMC3661610.
5. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, et al. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes. 2010; 59 (8):2027-32. doi: 10.2337/db09-1509 PMID: 20522598; PubMed Central PMCID: PMC2911054.
6. Gross S, van Ree RM, Oterdoom LH, de Vries AP, van Son WJ, de Jong PE, et al. Low levels of sRAGE are associated with increased risk for mortality in renal transplant recipients. Transplantation. 2007; 84(5):659-63. doi: 10.1097/01.tp.0000280556.16275.2a PMID: 17876282.
7. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012; 220 (1):208-14. doi: 10.1016/j.atherosclerosis.2011.07.115 PMID: 21906738.
8. Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care. 2009; 32(7):1218-20. doi: 10.2337/dc09-0053 PMID: 19366975; PubMed Central PMCID: PMC2699719.
9. Hudson BI, Moon YP, Kalea AZ, Khatri M, Marquez C, Schmidt AM, et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis. 2011; 216(1):192-8. doi: 10.1016/j.atherosclerosis.2011. 01.024 PMID: 21316677; PubMed Central PMCID: PMC3089661.
10. Investigators TA. The Atherosclerosis Risk in Communities (ARIC) Study: Design and Objectives. Am J Epidemiol. 1989; 129(4):687-702. PMID: 2646917
11. Genomes Project C, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, et al. A map of human genome variation from population-scale sequencing. Nature. 2010; 467(7319):1061-73. doi: 10.1038/nature09534 PMID: 20981092; PubMed Central PMCID: PMC3042601.
12. Delaneau O, Howie B, Cox AJ, Zagury JF, Marchini J. Haplotype estimation using sequencing reads. Am J Hum Genet. 2013; 93(4):687-96. doi: 10.1016/j.ajhg.2013.09.002 PMID: 24094745; PubMed Central PMCID: PMC3791270.
13. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006; 38(8):904-9. doi: 10.1038/ng1847 PMID: 16862161.
14. Bower JK, Pankow JS, Lazo M, Christenson E, Hoogeveen RC, Ballantyne CM, et al. Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). Clin Biochem. 2014; 47(1-2):132-4. doi: 10.1016/j.clinbiochem.2013.11.005 PMID: 24246851; PubMed Central PMCID: PMC4263345.
15. Center ARiCC. Operations manual no. 2: cohort component procedures, version 1.0. 1987.
16. Center ARiCC. Operations manual no. 10: clinical chemistry determinations, version 1.0. 1987.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. PMID: 10075613.
18. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007; 447(7145):661-78. doi: 10.1038/nature05911 PMID: 17554300; PubMed Central PMCID: PMC2719288.
19. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010; 26(18):2336-7. doi: 10.1093/bioinformatics/btq419 PMID: 20634204; PubMed Central PMCID: PMC2935401.
20. Therneau T.M. GPM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
21. Therneau T. A Package for Survival Analysis in R package version 2.37-4 2013 [cited 2013 November 7]. Available: http://CRAN.R-project.org/package=survival.
22. Rosner BA. Fundamentals of Biostatistics: Thomson-Brooks/Cole; 2006.
23. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013; 42(5):1497-501. doi: 10.1093/ije/dyt179 PMID: 24159078; PubMed Central PMCID: PMC3807619.
24. mRnd: Power calculations for Mendelian Randomization. Available: http://glimmer.rstudio.com/kn3in/mRnd/. Accessed: 2015 Jan 17.
25. Jang Y, Kim JY, Kang SM, Kim JS, Chae JS, Kim OY, et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism. 2007; 56 (2):199-205. doi: 10.1016/j.metabol.2006.09.013 PMID: 17224333.
26. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 188 (8):948-57. doi: 10.1164/rccm.201302-0247OC PMID: 23947473.
27. Yang L, Wu Q, Li Y, Fan X, Hao Y, Sun H, et al. Association of the receptor for advanced glycation end products gene polymorphisms and circulating RAGE levels with diabetic retinopathy in the Chinese population. J Diabetes Res. 2013; 2013:264579. doi: 10.1155/2013/264579 PMID: 24303504; PubMed Central PMCID: PMC3835200.
28. Gaens KH, Ferreira I, van der Kallen CJ, van Greevenbroek MM, Blaak EE, Feskens EJ, et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab. 2009; 94(12):5174-80. doi: 10.1210/jc.2009-1067 PMID: 19890027.
29. Peng F, Hu D, Jia N, Li X, Li Y, Chu S, et al. Association of Four Genetic Polymorphisms of AGER and Its Circulating Forms with Coronary Artery Disease: A Meta-Analysis. PLoS ONE. 2013; 8(7):e70834. doi: 10.1371/journal.pone.0070834 PMID: 23894685
30. Wang J, Zou L, Song Z, Lang X, Huang S, Lu F, et al. Meta-analysis of RAGE gene polymorphism and coronary heart disease risk. PLoS One. 2012; 7(12):e50790. doi: 10.1371/journal.pone.0050790 PMID: 23236395; PubMed Central PMCID: PMC3516500.
31. Zee RY, Romero JR, Gould JL, Ricupero DA, Ridker PM. Polymorphisms in the advanced glycosylation end product-specific receptor gene and risk of incident myocardial infarction or ischemic stroke. Stroke. 2006; 37(7):1686-90. Epub 2006/05/27. doi: 10.1161/01.STR.0000226994.93914.6c PMID: 16728681.
32. Yu X, Liu J, Zhu H, Xia Y, Gao L, Li Z, et al. An interactive association of advanced glycation end-product receptor gene four common polymorphisms with coronary artery disease in northeastern han chinese. PLoS One. 2013; 8(10):e76966. doi: 10.1371/journal.pone.0076966 PMID: 24155913; PubMed Central PMCID: PMC3796558.
33. Forbes JM, Soderlund J, Yap FY, Knip M, Andrikopoulos S, Ilonen J, et al. Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia. 2011; 54(5):1032-42. doi: 10.1007/s00125-011-2058-z PMID: 21298413.
34. Suchankova P, Klang J, Cavanna C, Holm G, Nilsson S, Jonsson EG, et al. Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism? J Psychiatry Neurosci. 2012; 37(2):122-8. doi: 10.1503/jpn.110024 PMID: 22146151; PubMed Central PMCID: PMC3297072.
35. Daborg J, von Otter M, Sjolander A, Nilsson S, Minthon L, Gustafson DR, et al. Association of the RAGE G82S polymorphism with Alzheimer's disease. J Neural Transm. 2010; 117(7):861-7. doi: 10. 1007/s00702-010-0437-0 PMID: 20567859; PubMed Central PMCID: PMC2895876.
36. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000; 1498(2-3):99-111. PMID: 11108954.
37. Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond). 2009; 116(8):621-37. doi: 10.1042/CS20080494 PMID: 19275767.
38. Kalea AZ, Schmidt AM, Hudson BI. Alternative splicing of RAGE: roles in biology and disease. Front Biosci (Landmark Ed). 2011; 16:2756-70. PMID: 21622207.
39. Herd P, Karraker A, Friedman E. The social patterns of a biological risk factor for disease: race, gender, socioeconomic position, and C-reactive protein. J Gerontol B Psychol Sci Soc Sci. 2012; 67(4):503-13. doi: 10.1093/geronb/gbs048 PMID: 22588996; PubMed Central PMCID: PMC3695599.
40. Majka DS, Chang RW, Vu TH, Palmas W, Geffken DF, Ouyang P, et al. Physical activity and high-sensitivity C-reactive protein: the multi-ethnic study of atherosclerosis. Am J Prev Med. 2009; 36(1):56-62. doi: 10.1016/j.amepre.2008.09.031 PMID: 19013748; PubMed Central PMCID: PMC4122519.
41. Gruenewald TL, Cohen S, Matthews KA, Tracy R, Seeman TE. Association of socioeconomic status with inflammation markers in black and white men and women in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Soc Sci Med. 2009; 69(3):451-9. doi: 10.1016/j.socscimed. 2009.05.018 PMID: 19524346; PubMed Central PMCID: PMC2747365.
42. Paul K, Boutain D, Agnew K, Thomas J, Hitti J. The relationship between racial identity, income, stress and C-reactive protein among parous women: implications for preterm birth disparity research. J Natl Med Assoc. 2008; 100(5):540-6. PMID: 18507206.
43. Cunningham TJ, Seeman TE, Kawachi I, Gortmaker SL, Jacobs DR, Kiefe CI, et al. Racial/ethnic and gender differences in the association between self-reported experiences of racial/ethnic discrimination and inflammation in the CARDIA cohort of 4 US communities. Soc Sci Med. 2012; 75(5):922-31. doi: 10.1016/j.socscimed.2012.04.027 PMID: 22682683; PubMed Central PMCID: PMC3417223.
44. VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P. Methodological challenges in mendelian randomization. Epidemiology. 2014; 25(3):427-35. doi: 10.1097/EDE.0000000000000081 PMID: 24681576; PubMed Central PMCID: PMC3981897.